e g neramexane may be combined with non toxic pharmaceutically acceptable excipients such as binding agents e g pregelatinized maize starch polyvinylpyrrolidone or hydroxypropyl methylcellulose fillers e g lactose sucrose glucose mannitol sorbitol and other reducing and non reducing sugars microcrystalline cellulose calcium sulfate or calcium hydrogen phosphate lubricants e g magnesium stearate talc or silica steric acid sodium stearyl fumarate glyceryl behenate calcium stearate and the like disintegrants e g potato starch or sodium starch glycolate or wetting agents e g sodium lauryl sulphate coloring and flavoring agents gelatin sweeteners natural and synthetic gums such as acacia tragacanth or alginates buffer salts carboxymethylcellulose polyethyleneglycol waxes and the like the tablets may be coated with a concentrated sugar solution which may contain e g gum arabic gelatine talcum titanium dioxide and the like alternatively the tablets can be coated with a polymer that dissolves in a readily volatile organic solvent or mixture of organic solvents in specific embodiments neramexane is formulated in immediate release ir or modified release mr dosage forms immediate release solid dosage forms permit the release of most or all of the active ingredient over a short period of time such as 60 minutes or less and make rapid absorption of the drug possible immediate release formulations of 1 amino alkylcyclohexanes such as neramexane are disclosed in us published application nos 2006 0002999 and 2006 0198884 the subject matter of which is hereby incorporated by reference modified release solid oral dosage forms permit the sustained release of the active ingredient over an extended period of time in an effort to maintain therapeutically effective plasma levels over similarly extended time intervals and or to modify.